Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 3/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | LDHB | P07195 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1595656 | 0.87 | CNR2 (0.42) | CNR2PDE2AAKR1C3AKR1C2CES2 | |
| SCHEMBL1595658 | 0.87 | CNR2 (0.42) | CNR2PDE2AAKR1C3AKR1C2CES2 | |
| SCHEMBL4292305 | 0.86 | PPARG (0.41) | CNR2PDE2AAKR1C3AKR1C2CES2 | |
| SCHEMBL2545456 | 0.80 | TRPV3 (0.42) | CNR2PDE2AAKR1C3AKR1C2CES2 | |
| SCHEMBL2545452 | 0.80 | TRPV3 (0.42) | CNR2PDE2AAKR1C3AKR1C2CES2 | |
| SCHEMBL1595429 | 0.79 | PDE2A (0.39) | CNR2PDE2AAKR1C3AKR1C2CES2 | |
| SCHEMBL1595431 | 0.79 | PDE2A (0.39) | CNR2PDE2AAKR1C3AKR1C2CES2 | |
| SCHEMBL1594709 | 0.78 | CNR2 (0.45) | CNR2PDE2AAKR1C3AKR1C2CES2 | |
| SCHEMBL1594711 | 0.78 | CNR2 (0.45) | CNR2PDE2AAKR1C3AKR1C2CES2 | |
| SCHEMBL2543293 | 0.77 | CNR2 (0.41) | CNR2PDE2AAKR1C3AKR1C2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | CNR2 2737/4885PDE2A 1439/4885AKR1C3 1548/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | CNR2 2083/4885PDE2A 1915/4885AKR1C3 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.